Premium
Adriamycin in advanced urinary tract cancer. Experience in 42 patients and review of the literature
Author(s) -
Yagoda Alan,
Watson Robin C.,
Whitmore Willet F.,
Grabstald Harry,
Middleman Mary P.,
Krakoff Irwin H.
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197701)39:1<279::aid-cncr2820390143>3.0.co;2-k
Subject(s) - medicine , urinary system , cancer
Forty‐two patients with measureable, advanced, genito‐urinary cancer received Adriamycin. Significant clinical responses (CR/PR) occurred in only five (14%) of 35 adequately treated patients. Four additional patients achieved a minimal response and four others showed stabilization of their disease for 4 to 9 months. Review of the literature suggests an overall response rate of 20%. Patients with a urinary diversion lived significantly longer (P 0.006) than patients who did not have this procedure (42.5 months vs 21.5 months). The need to define various patient characteristics in future chemotherapeutic trials in bladder cancer is discussed.